Ryan Bitar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan Bitar has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Julius Chapiro
Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT, 06520, USA; Department of Biomedical Engineering, School of Engineering and Applied Sciences, 17 Hillhouse Avenue, New Haven, CT, 06520, USA; Department of Medicine, Liver Center, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar St, New Haven, CT, 06520, USA
2 shared publications - Amado Zurita-Saavedra
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication Angelo G. Marino
Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
1 shared publicationAnnabella Shewarega
Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
1 shared publication- Annie Dang
Long School of Medicine, The University of Texas Health Sciences Center San Antonio, San Antonio, Texas
1 shared publication - Anthony Sisti
Department of Biostatistics, Brown University, Providence, RI, USA
1 shared publication
Latest Publications
- Open Access
Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure
Despite substantial improvement in the definitive management of primary prostate cancer, a significant number of patients experience biochemical recurrence—a clinical state in which serum prostate-specific antigen (PSA) levels rise prior to the development of physical signs or symptoms. The early detection and localization of biochemical recurrence may confer eligibility for salvage therapy; therefore, imaging techniques that provide accurate disease visualization are imperative. In this review, we discuss various imaging methods for localizing disease in the context of biochemical recurrence in prostate cancer. Particularly, we describe available or investigational positron emission tomography (PET) radiotracers, such as 18F-FDG, 18F-NaF, choline (both 18F and 11C), the 18F-labeled amino acid derivative fluciclovine, prostate-specific membrane antigen (PSMA) radioligands, and the short peptide compound bombesin. Generally, PET radiotracers such as 18F-FDG, 18F-NaF, and 18F/11C choline have fallen out of favor because of their inferior sensitivity and/or specificity in relation to more recently developed radiotracers. 18F-fluciclovine has addressed these shortcomings by exploiting the upregulation of amino acid transporters in tumors; however, PSMA-targeting agents have significantly advanced the management of biochemical recurrence of prostate cancer through their high sensitivity and specificity, enabling the identification of candidates for radionuclide therapy. Investigational agents, such as bombesin-based radiotracers, may address the shortcomings of treating prostate cancer with little to no PSMA expression.
Open AccessPositron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure
Despite substantial improvement in the definitive management of primary prostate cancer, a significant number of patients experience biochemical recurrence—a clinical state in which serum prostate-specific antigen (PSA) levels rise prior to the development of physical signs or symptoms. The early detection and localization of biochemical recurrence may confer eligibility for salvage therapy; therefore, imaging techniques that provide accurate disease visualization are imperative. In this review, we discuss various imaging methods for localizing disease in the context of biochemical recurrence in prostate cancer. Particularly, we describe available or investigational positron emission tomography (PET) radiotracers, such as 18F-FDG, 18F-NaF, choline (both 18F and 11C), the 18F-labeled amino acid derivative fluciclovine, prostate-specific membrane antigen (PSMA) radioligands, and the short peptide compound bombesin. Generally, PET radiotracers such as 18F-FDG, 18F-NaF, and 18F/11C choline have fallen out of favor because of their inferior sensitivity and/or specificity in relation to more recently developed radiotracers. 18F-fluciclovine has addressed these shortcomings by exploiting the upregulation of amino acid transporters in tumors; however, PSMA-targeting agents have significantly advanced the management of biochemical recurrence of prostate cancer through their high sensitivity and specificity, enabling the identification of candidates for radionuclide therapy. Investigational agents, such as bombesin-based radiotracers, may address the shortcomings of treating prostate cancer with little to no PSMA expression.
- 3 March 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (6) , 1042-1050.e2
Portal and Hepatic Vein Embolization versus Portal Venous Embolization Alone in Cirrhotic and Noncirrhotic Swine: A Pilot Study
- 3 March 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (6) , 1042-1050.e2
Portal and Hepatic Vein Embolization versus Portal Venous Embolization Alone in Cirrhotic and Noncirrhotic Swine: A Pilot Study
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 6 (6) , e240660
Breaking Ground on the Application of AI to HCC: It’s All about Data
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 6 (6) , e240660
Breaking Ground on the Application of AI to HCC: It’s All about Data
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (2) , e232875
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma
This review discusses mechanisms behind the immunosuppressive tumor microenvironment, the influence of locoregional therapy on immunotherapy, and the development of imaging and serologic biomarkers in relation to hepatocellular carcinoma.
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (2) , e232875
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma
This review discusses mechanisms behind the immunosuppressive tumor microenvironment, the influence of locoregional therapy on immunotherapy, and the development of imaging and serologic biomarkers in relation to hepatocellular carcinoma.
- 13 September 2024
- Published by Wolters Kluwer Health in Ultrasound Quarterly
- Vol. 40 (4)
Residual Ultrasound-Enhancing Agents Mimicking Portal Venous Gas
Sonographic detection of mobile echogenic foci within the main portal vein and its branches or within the liver parenchyma extending along the portal triads to the periphery of the liver is an alarming finding that has been associated with portal venous gas in the setting of bowel ischemia. Ultrasound-enhancing agents (UEAs) have been widely utilized in abdominal ultrasound for evaluation of organ neoplasms and vascular patency as well as in echocardiography for the evaluation of cardiac function. The appearance of UEAs on abdominal ultrasound can resemble gas like that seen in the portal venous system and liver in patients with bowel ischemia; therefore, UEA residuals should always be a part of the differential diagnosis of echogenic foci when seen on abdominal ultrasounds with preceding recent UEA administration. In this observational study, we present a series of cases with suspected portal venous gas suspicious for bowel ischemia that turned out to be a result of residual or persistent UEA from the recent contrast-enhanced echocardiography. Discussion of this phenomenon and its potential explanation is provided.
- 13 September 2024
- Published by Wolters Kluwer Health in Ultrasound Quarterly
- Vol. 40 (4)
Residual Ultrasound-Enhancing Agents Mimicking Portal Venous Gas
Sonographic detection of mobile echogenic foci within the main portal vein and its branches or within the liver parenchyma extending along the portal triads to the periphery of the liver is an alarming finding that has been associated with portal venous gas in the setting of bowel ischemia. Ultrasound-enhancing agents (UEAs) have been widely utilized in abdominal ultrasound for evaluation of organ neoplasms and vascular patency as well as in echocardiography for the evaluation of cardiac function. The appearance of UEAs on abdominal ultrasound can resemble gas like that seen in the portal venous system and liver in patients with bowel ischemia; therefore, UEA residuals should always be a part of the differential diagnosis of echogenic foci when seen on abdominal ultrasounds with preceding recent UEA administration. In this observational study, we present a series of cases with suspected portal venous gas suspicious for bowel ischemia that turned out to be a result of residual or persistent UEA from the recent contrast-enhanced echocardiography. Discussion of this phenomenon and its potential explanation is provided.
- 29 June 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (10) , 1447-1456
Effect of Filtered Blood Return on Outcomes of Pulmonary Aspiration Thrombectomy
- 29 June 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (10) , 1447-1456
Effect of Filtered Blood Return on Outcomes of Pulmonary Aspiration Thrombectomy
- Open Access
- 21 March 2023
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 9 (2) , 101124
Direct stick embolization of a rectal venous malformation via transanal minimally invasive surgery
- 21 March 2023
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 9 (2) , 101124
Open AccessDirect stick embolization of a rectal venous malformation via transanal minimally invasive surgery
- 14 October 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (1) , 40-45.e2
Creation of an Ex Vivo Renal Perfusion Model to Investigate Microwave Ablation
- 14 October 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (1) , 40-45.e2
Creation of an Ex Vivo Renal Perfusion Model to Investigate Microwave Ablation